Literature DB >> 24967886

What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review.

Sadie Wickwar1, Hayley B McBain, Daniel G Ezra, Shashivadan P Hirani, Geoffrey E Rose, Stanton P Newman.   

Abstract

BACKGROUND: Thyroid eye disease (TED) causes a number of esthetic and visual problems, and its treatment requires close clinical assessment, often for several years. There is evidence to suggest that clinical factors are poor indicators of patient-reported outcomes after treatments that aim to improve appearance, vision, or both. Psychosocial factors can impact on both adjustment to living with TED and also patients' perceptions of their improvements after treatment. There has been growing recognition that it is essential to evaluate treatment efficacy in terms of psychosocial outcomes, but, to date, there has been no review that has systematically evaluated psychosocial outcomes following a variety of treatments for TED.
SUMMARY: Fifteen studies were included in the review, and six were randomized controlled trials. The studies varied greatly in methodological rigor; whilst major treatments such as surgery do improve quality of life outcomes, other noninvasive treatments such as intravenous steroids can have a similar impact and show long-term benefits. Only three studies reviewed orbital decompressive surgery, which showed better psychosocial outcomes than other types of surgery.
CONCLUSIONS: The effect of some treatments remains unclear due to poor methodology and poor reporting of results. Clinicians need to be aware when planning rehabilitative treatments such as surgery of the influence of psychosocial factors on quality of life outcomes and the lack of a relationship with clinical factors such as disease severity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24967886     DOI: 10.1089/thy.2014.0037

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  7 in total

1.  A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.

Authors:  Soma Farag; Claire Feeney; Vickie Lee; Sonali Nagendran; Rajni Jain; Ahmad Aziz; Rashmi Akishar; Vassiliki Bravis; Karim Meeran
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-07       Impact factor: 5.555

2.  Mechanisms of Spica Prunellae against thyroid-associated Ophthalmopathy based on network pharmacology and molecular docking.

Authors:  Yuhan Zhang; Xianzhi Li; Congcong Guo; Jianjun Dong; Lin Liao
Journal:  BMC Complement Med Ther       Date:  2020-07-20

Review 3.  Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures.

Authors:  Samia Al Jabri; Jamie Kirkham; Fiona J Rowe
Journal:  BMC Ophthalmol       Date:  2019-02-08       Impact factor: 2.209

4.  The value of SPECT/CT imaging of lacrimal glands as a means of assessing the activity of Graves' orbitopathy.

Authors:  Ru-Xuan Zhao; Ting-Ting Shi; Sha Luo; Yun-Fu Liu; Zhong Xin; Jin-Kui Yang
Journal:  Endocr Connect       Date:  2022-02-09       Impact factor: 3.335

5.  Improvement of asymmetric thyroid eye disease with teprotumumab.

Authors:  Shoaib Ugradar; Yao Wang; Tunde Mester; George J Kahaly; Raymond Douglas
Journal:  Br J Ophthalmol       Date:  2021-02-12       Impact factor: 5.908

6.  Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.

Authors:  Laura Moi; Mehrad Hamedani; Camillo Ribi
Journal:  Clin Endocrinol (Oxf)       Date:  2021-12-14       Impact factor: 3.523

Review 7.  Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review.

Authors:  Nickisa M Hodgson; Fatemeh Rajaii
Journal:  Ophthalmol Ther       Date:  2019-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.